Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

Zeller heads FDA tobacco center; FDA denies P&G diabetes claim; Meda depends on OTCs; Ocean Nutrition boosts DSM; Elcelyx innovates in financing round; FDA warns DMAA firm on GMP violations; probiotics get Canadian claim approval.

You may also be interested in...



US HBW Executive Decisions: FDA's Zeller Retires; CHPA, GOED Additions; ACI VP On ITAC3

Mitch Zeller retires more than 30 year career in tobacco policy; Logan Tucker joins CHPA communications director; GOED hires Ashely Becnel as global business development director; ACI VP Kathleen Stanton appointed to Industry Trade advisory committee.

In Brief

Hi-Tech absorbs hit from Sandy; Meda strikes MidNite deal; Sunscreen labeling due date nears; ChromaDex picks up Spherix Consulting; Chemi Pharmaceutical allegedly falsified tests; Actavis exec Boothe joins Perrigo.

ConAgra’s Petition For Whole Grain/Diabetes Claim Draws Opposition

Kellogg Co. disagrees with ConAgra’s petition to FDA for a qualified health claim linking whole grain consumption with reduced risk of type 2 diabetes. Other experts question ConAgra’s supporting evidence and maintain fiber content should be emphasized over whole grains in product labeling.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS106245

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel